About Fluidigm
Fluidigm is a publicly listed company based in San Francisco (United States) founded in 1999. Instruments for life sciences research and applications are developed. Fluidigm has raised $40.53 million across 10 funding rounds from investors including AllianceBernstein, European Union and Viking Global Investors. The company has 205 employees. Fluidigm has completed 3 acquisitions, including ARCXIS, DVS Sciences and InstruNor. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Diversified. Its legal entity is FLUIDIGM CORPORATION. Its competitors include Cepheid, Beckman Coulter and Blackrock Neurotech; 2 of its 3 listed competitors have raised funding.
Company details
Fluidigm was founded in 1999 in San Francisco, United States, and operates within the life sciences sector. Instruments and platforms are provided for applications such as next-generation sequencing library preparation, single-cell PCR, genomics, epigenomics, and transcriptomics. Key products include the Access Array and Juno systems, Biomark HD and EP1 for genotyping assays, C1 for single-cell analysis, and Callisto for long-term cell culture experiments. Operations focus on biotechnology tools distributed globally.
- Headquarters San Francisco, United States
- Employees 205
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website fluidigm.com
- Social LinkedIn X Facebook
- Legal Name Fluidigm Corporation
- Total Equity Funding$40.53M (USD)
in 10 rounds
- Latest Funding Round$250M (USD), Post-IPO
Apr 2022
- InvestorsAllianceBernstein
& 15 more
- Employee Count205
- Investments & AcquisitionsARCXIS
& 2 more
Funding Insights of Fluidigm
Fluidigm has successfully raised a total of $40.53M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40.53M
- Total Rounds 10
- Last Round Post-IPO — $250M
- Investors Count 16
All 10 funding rounds of Fluidigm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $250M | Post-IPO | – | – | |
| Dec 2020 | $26,015 | Grant | – | – | |
| Nov 2019 | $45M | Post-IPO | – | – | – |
| Mar 2018 | $125M | Post-IPO | – | – | – |
| Jan 2017 | $37M | Post-IPO | – | – | |
| Jan 2014 | $175M | Post-IPO | – | – | – |
| Jan 2011 | $5M | Series B | – | – | – |
| Nov 2009 | $18.53M | Series B | – | Alloy Ventures, EDBI | – |
| Jan 2007 | $17M | Series B | – | Cross Creek, Wasatch Advisors | |
| Nov 2004 | Series A | – | In-Q-Tel | – |
16 investors in total: 16 institutional.
Investors in Fluidigm
Fluidigm has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include AllianceBernstein, European Union and Viking Global Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Sector-agnostic investments in late-stage startups are made by Cross Creek. | crosscreek.vc | Salt Lake City, United States | ||
Early stage venture capital firm investing in the US | alloyventures.com | Palo Alto, United States | ||
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
| euclidsr.com | ||||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States |
Investor details for Fluidigm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fluidigm
94 people are tracked at Fluidigm (43 in leadership, 51 in team); the tracked headcount is 205.
| Name | Role | Group |
|---|---|---|
Daaf Sandkuijl | Senior Director, R&d | Leadership |
James R. Mansfield | VP Business Development Imaging | Leadership |
Bermet Abylova | Director Of Sales, APAC | Leadership |
Caron Winslow | Senior Director Of Strategic Alliances | Leadership |
Evaldas Katilius | Senior Director | Leadership |
Charles Park | Vice President Of Microfluidics R&d | Leadership |
Ashley Cate | Director Of Fp&a | Leadership |
Lauren Crowe | Global Vice President, Finance | Leadership |
Stephen A. Williams | Chief Medical Officer | Leadership |
David Panzarella | Vice President And Commercial General Manager - Americas And EMEA | Leadership |
Alex Kim | COO | Leadership |
Dan Schneider | Vice President, Technology Research | Leadership |
Suan Jap | Director, Design Transfer R&d | Leadership |
Michael Egholm | President & CEO | Leadership |
Jeff Black | CFO | Leadership |
Madeleine Churchill | Global Creative Director | Leadership |
Sean MacKay | SVP & Chief Business Officer | Leadership |
Chris Leidel | Vice President Of Business Development | Leadership |
Mark Messenbaugh | Vice President - Strategic Alliance Development | Leadership |
Anders Davas | Senior Vice President - Global Operations | Leadership |
74 more people are available in the full profile.
Complete people profiles for Fluidigm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fluidigm
Fluidigm has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include ARCXIS, DVS Sciences and InstruNor.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer of cancer and immune system treatment devices | instrunor.com | 2011 | Feb 2020 | $7.2M | ||
Novel bioanalytical solutions are manufactured and distributed globally. | dvssciences.com | San Francisco, United States | 2004 | Jan 2014 | $207.5M | |
Construction management services are offered to residential builders. | arcxis.com | Pleasanton, United States | 2004 | Jun 2013 | •••• |
Complete acquisition details for Fluidigm
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Fluidigm
7 dated milestones of Fluidigm across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Fluidigm is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ARCXIS.
- Acquisition Acquires DVS Sciences.
- Acquisition Acquires InstruNor.
- Funding Latest funding round, Post-IPO, of $250.0M.
Competitors of Fluidigm
Fluidigm has 3 listed competitors in our database, 2 of them funded. They include Cepheid, Beckman Coulter and Blackrock Neurotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| beckman.com | 1935 | Brea, United States | Provider of products for biomedical testing for R&D, diagnostic and commercial applications | |||
| blackrockneurotech.com | 2008 | Salt Lake, United States | $22.37M | 127 | Medical devices for neurological therapies are developed. |
Detailed competitors of Fluidigm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fluidigm
The website of Fluidigm (fluidigm.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 142.1% vs previous month
Websites whose visitors overlap most with Fluidigm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| raindancetech.com | 100% | View details | |||
| illumina.com | 91% | 672.7K | #61,793 | View details | |
| dvssciences.com | 86% | View details | |||
| affymetrix.com | 78% | 1.1K | #9,164,392 | View details | |
| appliedbiosystems.com | 76% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Fluidigm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Fluidigm (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fluidigm
Complete news archive for Fluidigm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fluidigm
Fluidigm was founded in 1999 and raised its 1st funding round 5 years after it was founded.
Fluidigm is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fluidigm is a funded company, having raised a total of $40.53M across 10 funding rounds to date.
Fluidigm has 205 employees.
Fluidigm was founded in 1999 in San Francisco, United States, and operates within the life sciences sector. Instruments and platforms are provided for applications such as next-generation sequencing library preparation, single-cell PCR, genomics, epigenomics, and transcriptomics. Key products include the Access Array and Juno systems, Biomark HD and EP1 for genotyping assays, C1 for single-cell analysis, and Callisto for long-term cell culture experiments. Operations focus on biotechnology tools distributed globally.
Fluidigm's top competitors include Cepheid, Blackrock Neurotech and Beckman Coulter.
Fluidigm has made 3 acquisitions, including ARCXIS, DVS Sciences, and InstruNor.
Fluidigm has 16 investors. Key investors include AllianceBernstein, European Union, Viking Global Investors, Casdin Capital, and Cross Creek.
Fluidigm operates through Fluidigm Corporation.